SAN FRANCISCO – March 15, 2022 – NephroSant™, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been…
SAN FRANCISCO, March 3, 2022 /PRNewswire/ — NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that the Journal of Clinical…
SAN FRANCISCO – January 3, 2022 – NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced…
